Group 1: Company Overview and Growth Prospects - Kailaiying Pharmaceutical Group is focusing on expanding its peptide business, which is currently the fastest-growing segment, with 19 clinical projects in the GLP-1, Amylin, and cyclic peptide areas, 8 of which are in late-stage clinical trials [2][3] - The company has seen significant growth and structural changes in its service pipeline over the past two years, with over 50 peptide projects extending beyond weight loss to autoimmune and other fields [3] Group 2: Production Capacity and Capital Expenditure - The small molecule business is operating at high capacity, with the TJ3 plant expected to alleviate API capacity constraints by Q2 2026 [4] - The total capital expenditure plan for 2026 is approximately RMB 2.1 billion, with 70%-80% allocated to emerging business segments, particularly in chemical and biological macromolecules [4] Group 3: Revenue and Profitability Outlook - The company anticipates a revenue growth of 19%-22% for 2026, with a potential 2-3 percentage point increase under constant exchange rates [5] - Emerging business segments are expected to see continuous improvement in gross margins due to factors such as increased overseas revenue share and enhanced capacity utilization [5] Group 4: Order Growth and Market Demand - As of the end of Q1 2026, the total order backlog is USD 1.385 billion, reflecting a 31.65% year-over-year increase, driven by sustained growth in small molecule commercialization projects [6][8] - The demand for new molecular types, such as conjugated drugs and peptides, is robust, with a notable scarcity in production capacity [7] Group 5: Strategic Initiatives and Challenges - The company is actively managing cost impacts from rising chemical prices due to geopolitical tensions, with proactive procurement strategies in place [5] - There is ongoing exploration of overseas capacity expansion, aligned with business development efforts, although the pace remains cautious [6]